Evofem Biosciences, Inc (EVFM)

Etorro trading 970x250
Evofem Biosciences, Inc (EVFM) Logo

About Evofem Biosciences, Inc

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California. Address: 12400 High Bluff Drive, San Diego, CA, United States, 92130

Evofem Biosciences, Inc News and around…

Latest news about Evofem Biosciences, Inc (EVFM) common stock and company :

Mid-Afternoon Market Update: Dow Dips Over 500 Points; Ross Stores Shares Slide
20 May, 2022 FinancialContent

U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 500 points on Friday. The Dow traded ...

12 Health Care Stocks Moving In Friday's Intraday Session
20 May, 2022 FinancialContent

Gainers Immix Biopharma (NASDAQ:IMMX) shares increased by 52.1% to $2.48 during Friday's regular session. The ...

Mid-Day Market Update: Dow Tumbles 200 Points; TherapeuticsMD Shares Jump
20 May, 2022 FinancialContent

U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 200 points on Friday. The Dow traded down 0.64% ...

38 Stocks Moving In Friday's Mid-Day Session
20 May, 2022 FinancialContent

Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413. TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 25.6% to ...

Why Evofem Biosciences Shares Are Getting Hammered Today
20 May, 2022 FinancialContent

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly ...

Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering
20 May, 2022 Yahoo! Finance

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000 pre-funded warrants to purchase common stock in lieu of common stock to certain investors and warrants to purchase up to 71,000,000 shares of its common stock. Each share of common stock and accompanying common warrant are being offered at a combined public offering price of $0.75, less underwriting discounts an

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
20 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
20 May, 2022 FinancialContent

Gainers Exicure (NASDAQ:XCUR) shares rose 24.8% to $0.15 during Friday's pre-market session. The company's ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
20 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're closing in on the end of the week for trading as we go over the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

20 Stocks Moving in Friday's Pre-Market Session
20 May, 2022 FinancialContent

Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director ...

Evofem Biosciences Announces Proposed Public Offering
19 May, 2022 Yahoo! Finance

Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common stock to certain investors) and warrants to purchase shares of its common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the of

Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®
10 May, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has selected Bora Pharmaceuticals Services Inc. (Bora) Canada as Evofem's new contract manufacturing organization (CMO). Bora will eventually manufacture Phexxi® (lactic acid, citric acid, and potassium bitartrate) for markets worldwide.

Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial
06 May, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi® (lactic acid, citric acid, and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to the general population.

83 Biggest Movers From Yesterday
06 May, 2022 FinancialContent

Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported ...

Evofem Biosciences Announces 1-for-15 Reverse Stock Split
05 May, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at the annual meeting of the Company held on May 4, 2022. The reverse stock split will take effect at the close of trading on the Nasdaq Capital Market, or 4:00 p.m. Eastern Time, on Thursday, May 5, 2022. The Company's common stock will open for trading under a new CUSIP on the Nasdaq Capital Market on May 6

Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
04 May, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2022.

20 Stocks Moving in Tuesday's Pre-Market Session
03 May, 2022 FinancialContent

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and ...

We Asked, You Answered: What Stock Would You Never Buy Again?
02 May, 2022 FinancialContent

Almost all traders have had that moment:A confident stock pick or strategy that backfires and leaves the investor with less money ...

Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services
27 Apr, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has entered into a new agreement with VitaCare Prescription Services, a wholly-owned subsidiary of GoodRx, to provide enhanced "white glove" support services to women prescribed Phexxi® (lactic acid, citric acid, potassium bitartrate) who choose to use VitaCare. Women or their health care provider can choose to have a Phexxi prescription sent to VitaCare for fulfillment, and VitaCare will help the patient understand coverage, ident

Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting
26 Apr, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists (ACOG) annual meeting. The poster presentation details the characterization of women who experienced urinary tract infections (UTIs) during the AMPOWER Study.

Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022
25 Apr, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022 as follows:

Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial
19 Apr, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the Journal of Sexual Medicine, a peer-reviewed medical journal, published data collected from Evofem's Phase 3 AMPOWER clinical trial. Analysis of exploratory endpoints shows that 88.7% of women using Phexxi® (lactic acid, citric acid, and potassium bitartrate) reported improvement (n=44.7%) in or the maintenance (n=44%) of their sexual satisfaction. The publication can be found here: https://www.jsm.jsexmed.org/article/S1743-6095(22)0083

Evofem Announces Karina Fedasz as Company's New Head of Business Development
11 Apr, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem, Karina will oversee the company's business development, product and pipeline portfolios, new business ventures, and the advancement of access partnerships around the world.

Stocks That Hit 52-Week Lows On Friday
08 Apr, 2022 FinancialContent

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week ...

Nasdaq Accepts Evofem Plan to Regain Listing Compliance
07 Apr, 2022 Yahoo! Finance

Evofem Biosciences, Inc. (Nasdaq: EVFM) ("Evofem" and the "Company"), a commercial-stage biopharmaceutical company, today announced the Nasdaq Hearings Panel (the "Panel") has granted Evofem's request to continue its listing on The Nasdaq Stock Market ("Nasdaq"), pending the outcome of the stockholder vote on the Company's reverse stock split proposal scheduled to take place at its annual general meeting on May 4, 2022.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
05 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It's time to start off another busy day of trading with the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
31 Mar, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) today presented data at the Academy of Managed Care Pharmacy (AMCP) annual meeting showing EVO100 (the investigational name for Phexxi®) provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product. The results are based on Evofem's Phase 2B/3 AMPREVENCE clinical trial. Additional data from the AMPREVENCE trial were collected to

Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women
04 Mar, 2022 Yahoo! Finance

Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has completed enrollment in EVOGUARD, the registrational Phase 3 clinical trial evaluating EVO100 (the investigational name for Phexxi® (lactic acid, citric acid, potassium bitartrate)) for two potential new indications: the prevention of chlamydia infection in women and the prevention of urogenital gonorrhea infection in women.

12 Health Care Stocks Moving In Thursday's After-Market Session
03 Mar, 2022 FinancialContent

Gainers Puma Biotechnology (NASDAQ:PBYI) shares moved upwards by 12.0% to $2.61 during Thursday's after-market session. The company's ...

Evofem Biosciences: Q4 Earnings Insights
03 Mar, 2022 FinancialContent

Evofem Biosciences (NASDAQ:EVFM) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors ...

Evofem Biosciences, Inc (EVFM) is a NASDAQ Common Stock listed in , ,

970x250